Zacks: Brokerages Anticipate Bausch Health Companies Inc (BHC) Will Post Earnings of $0.88 Per Share

Wall Street analysts expect Bausch Health Companies Inc (NYSE:BHC) to announce earnings of $0.88 per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Bausch Health Companies’ earnings, with the highest EPS estimate coming in at $1.01 and the lowest estimate coming in at $0.66. Bausch Health Companies reported earnings per share of $0.98 during the same quarter last year, which suggests a negative year over year growth rate of 10.2%. The company is scheduled to report its next earnings report on Wednesday, February 27th.

On average, analysts expect that Bausch Health Companies will report full year earnings of $3.81 per share for the current financial year, with EPS estimates ranging from $3.60 to $3.96. For the next fiscal year, analysts anticipate that the firm will report earnings of $3.85 per share, with EPS estimates ranging from $3.63 to $4.14. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that follow Bausch Health Companies.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Tuesday, November 6th. The company reported $1.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.84 by $0.31. The business had revenue of $2.14 billion during the quarter, compared to analyst estimates of $2.09 billion. Bausch Health Companies had a positive return on equity of 32.19% and a negative net margin of 40.41%. Bausch Health Companies’s quarterly revenue was down 3.7% on a year-over-year basis.

Several equities research analysts have recently issued reports on the company. Mizuho lifted their price target on Bausch Health Companies from $35.00 to $38.00 and gave the company a “buy” rating in a report on Friday, November 30th. BMO Capital Markets reiterated a “hold” rating and set a $26.00 price target on shares of Bausch Health Companies in a report on Tuesday, November 13th. ValuEngine lowered Bausch Health Companies from a “hold” rating to a “sell” rating in a report on Monday, November 12th. TD Securities lifted their price target on Bausch Health Companies from $24.00 to $28.00 and gave the company a “hold” rating in a report on Wednesday, November 7th. Finally, Royal Bank of Canada lifted their price target on Bausch Health Companies from $30.00 to $31.00 and gave the company a “hold” rating in a report on Wednesday, November 7th. Three analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company. Bausch Health Companies currently has a consensus rating of “Hold” and a consensus price target of $28.18.

Shares of Bausch Health Companies stock traded down $0.22 during trading on Friday, hitting $24.25. 3,979,391 shares of the stock traded hands, compared to its average volume of 7,695,741. The firm has a market cap of $8.56 billion, a price-to-earnings ratio of 6.28, a P/E/G ratio of 0.32 and a beta of -0.28. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.14 and a quick ratio of 0.91. Bausch Health Companies has a twelve month low of $14.44 and a twelve month high of $28.45.

In related news, Director Schutter Richard U. De acquired 125,000 shares of the business’s stock in a transaction that occurred on Thursday, September 13th. The shares were acquired at an average cost of $23.96 per share, with a total value of $2,995,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Joseph C. Papa acquired 30,000 shares of the business’s stock in a transaction that occurred on Friday, September 14th. The stock was bought at an average cost of $22.32 per share, for a total transaction of $669,600.00. The disclosure for this purchase can be found here. Insiders purchased a total of 165,000 shares of company stock worth $3,890,700 over the last three months. 11.54% of the stock is owned by company insiders.

Several hedge funds have recently modified their holdings of the stock. NEXT Financial Group Inc bought a new position in shares of Bausch Health Companies in the 3rd quarter valued at approximately $101,000. Steward Partners Investment Advisory LLC bought a new position in shares of Bausch Health Companies in the 3rd quarter valued at approximately $106,000. Polaris Greystone Financial Group LLC bought a new position in shares of Bausch Health Companies in the 3rd quarter valued at approximately $107,000. Quadrant Capital Group LLC bought a new position in shares of Bausch Health Companies in the 3rd quarter valued at approximately $118,000. Finally, Bedel Financial Consulting Inc. bought a new position in shares of Bausch Health Companies in the 3rd quarter valued at approximately $129,000. 50.09% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.

See Also: Catch-Up Contributions

Get a free copy of the Zacks research report on Bausch Health Companies (BHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply